A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Clinical trial NCT03260322 · COMPLETED
Trial details
- NCT number
- NCT03260322
- Sponsor
- Astellas Pharma Global Development, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-09-08
- Primary completion
- 2022-05-10
- Enrollment
- 169
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.